From Low-Positive Fixed Cell-Based Assay to Confirmed Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Paediatric Case Report
Sclerosis · 29.04.2026 · 4 (2) · 9
DOI: 10.3390/sclerosis4020009 ↗Kurz gefasst
Fallbericht in der Zeitschrift Sclerosis, online erschienen am 29.04.2026. Verfasst von Tamara Santibáñez und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) relies on sensitive serological detection of MOG-IgG. Fixed cell-based assays (CBAs) may yield low-positive or borderline results that complicate early clinical decision-making, whereas live CBAs—recommended as the reference method—preserve native antigen conformation and offer higher analytical sensitivity. Importantly, low-positive titres should not be confused with true seronegativity, as they may nevertheless be clinically meaningful. Case Presentation: A 14-year-old previously healthy male presented with left optic neuritis and perineuritis following an upper respiratory infection. Initial MOG-IgG testing on a fixed CBA was low-positive (1:10). He partially responded to intravenous methylprednisolone and required intravenous immunoglobulin (IVIG) for complete resolution. Over three years, he experienced sequential, steroid-dependent bilateral optic neuritis with perineuritis, relapsing on every steroid taper. Rituximab and subsequently mycophenolate mofetil failed to induce remission. Repeat testing with a live CBA at a reference laboratory yielded a high-positive MOG-IgG titre of 1:1000, confirming MOGAD. Tocilizumab (8 mg/kg every 4 weeks) was initiated and allowed complete corticosteroid withdrawal. At age 18, the patient remained asymptomatic, with an Expanded Disability Status Scale score of 0, best-corrected visual acuity of 20/20 in both eyes, and stable peripapillary retinal nerve fibre layer thickness on spectral-domain optical coherence tomography.
Conclusions
In paediatric patients with recurrent optic neuritis with perineural involvement and borderline fixed-CBA results, confirmatory testing with a live CBA at a reference laboratory should be considered to avoid diagnostic delay and therapeutic misdirection. In refractory, steroid-dependent cases, IL-6 receptor blockade may represent a reasonable therapeutic option, in line with emerging evidence.
Zitieren
APA
Santibáñez, T., Valdés, J. M., & Galleguillos, L. (2026). From Low-Positive Fixed Cell-Based Assay to Confirmed Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Paediatric Case Report. Sclerosis, 4(2), 9. https://doi.org/10.3390/sclerosis4020009
Vancouver
Santibáñez T, Valdés JM, Galleguillos L. From Low-Positive Fixed Cell-Based Assay to Confirmed Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Paediatric Case Report. Sclerosis. 2026;4(2):9. doi:10.3390/sclerosis4020009
BibTeX
@article{Santibez2026,
author = {Santibáñez, Tamara and Valdés, José M. and Galleguillos, Lorna},
title = {From Low-Positive Fixed Cell-Based Assay to Confirmed Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Paediatric Case Report},
journal = {Sclerosis},
year = {2026},
volume = {4},
number = {2},
pages = {9},
doi = {10.3390/sclerosis4020009}
}
EUVIMED